Primary Surgery Tops Neoadjuvant Chemo in Epithelial Ovarian Cancer?


A retrospective review showed that primary cytoreductive surgery was associated with longer survival than neoadjuvant chemotherapy in women with advanced-stage epithelial ovarian cancer.

A retrospective review showed that primary cytoreductive surgery (PCS) was associated with longer survival than neoadjuvant chemotherapy (NACT) in women with advanced-stage epithelial ovarian cancer. This could be explained by poorer performance status among those undergoing NACT, however.

“The role of NACT in the treatment of epithelial ovarian cancer remains controversial,” wrote study authors led by J. Alejandro Rauh-Hain Fernandez, MD, of Massachusetts General Hospital in Boston. Several retrospective studies have favored PCS over NACT, while two phase III randomized trials demonstrated noninferiority of NACT in women with high disease burden. All the studies have had some methodologic issues, though.

The new analysis included 22,962 women under the age of 70 included in the National Cancer Database who were treated for stage IIIC and IV epithelial ovarian cancer who were diagnosed between 2003 and 2011. Of those, 19,836 (86.4%) were treated with PCS, and 3,126 (13.6%) received NACT; a propensity-matched analysis included 2,935 patients from each treatment group. The results were published online ahead of print in JAMA Oncology.

The median overall survival duration in the propensity-matched analysis was 37.3 months with PCS, and 32.1 months with NACT, for a hazard ratio (HR) of 1.18 (95% CI, 1.11–1.26). Both groups saw improved survival in later years of the study period compared to earlier years of diagnosis, but the association of improved survival with PCS remained as both groups’ survival lengthened.

The difference was slightly more pronounced in stage IIIC patients, with an HR of 1.24 (95% CI, 1.11–1.37) in favor of PCS. In stage IV patients, the HR was 1.13 (95% CI, 1.04–1.23).

Sensitivity analyses of unobserved variables found that the results would be robust to large differences in prevalence of high disease burden and to BRCA mutation status. However, the improvement in survival could be explained by differences in performance status; if 60% of women receiving NACT had an ECOG performance status of 1 to 2 compared with 50% in the PCS group, that would negate the difference in survival.

“Such information will be important to collect for future observational studies,” the authors wrote. “Future research should focus on which patients benefit most from PCS or NACT to tailor the treatment of women with advanced-stage epithelial ovarian cancer.”

Related Videos
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.
Brian Slomovitz, MD, MS, FACOG, notes that sometimes there is a need to substitute cisplatin for carboplatin, and vice versa, to best manage gynecologic cancers during the chemotherapy shortage.
Findings from the phase 3 MIRASOL trial support mirvetuximab soravtansine as a standard treatment option for platinum-resistant ovarian cancer, according to Ritu Salani, MD.
Trastuzumab deruxtecan appears to elicit ‘impressive’ responses among patients with HER2-positive gynecologic cancers regardless of immunohistochemistry in the phase 2 DESTINY-PanTumor02 trial.
Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.
Related Content